Clinical Diagnostics

PGxInsight - Cardiovascular

Millions of Americans currently take cardiovascular medications to treat or prevent heart disease and many have had problems finding the right drug and dose. Over half of all medications, including the majority of heart disease medications, are metabolized by enzymes in the liver. Gene variation is the main factor determining enzyme levels in the liver. If you have too much of the enzyme, you process the medication too quickly: too little of the enzyme and the medication builds up in your bloodstream, potentially causing adverse reactions or side effects. Without knowing your genetics, your physician may need to go through months of trial-and-error prescribing to find the right drug and dose for you.
Tests offered by Retrogen include the CYP2D6, CYP2C9, CYP2C19, VKORC1, SLCO1B1, CYP3A4, CYP3A5, MTHFR, Factor V Leiden, Factor II, and APOE genes. Variation in the Apolipoprotein E gene is associated with increased risk of hyperlipidemia/atherosclerotic vascular disease. Variation in the Factor II and Factor V Leiden genes is associated with increased thrombosis risk. Genetic variants in the MTHFR gene are associated with increased risk of hyperhomocysteinemia. Variation in the SLCO1B1 gene is associated with increased risk of myopathy. Variation in the VKORC1 gene is associated with increased risk of warfarin sensitivity.

Available Tests
Cardiovascular Panel
Documents
Info Sheet  Requisition Form 
Test Information
Genes: CYP2D6, CYP2C9, CYP2C19, VKORC1, SLCO1B1, CYP3A4, CYP3A5, MTHFR,
Factor V Leiden, Factor II, APOE
Clinical Utility:
Method: Polymerase Chain Reaction and Sanger Sequencing
Ordering
Test ID: #9002 Cardiovascular Panel
Turn-around Time: 5-8 days
Preferred Specimen: Buccal swabs
Billing
CPT Codes: 81479
Billing Information: View Billing Information
References
  1. Thase ME. STEP-BD and bipolar depression: what have we learned? Curr Psychiatry Rep 2007; 9: 497-503.
  2. Kung S, Xiaofan L. The clinical use of pharmacogenomic testing in treatment-resistant depression. Prim psychiatry 2010; 17: 46-51.
  3. Mulder H, Heerdink ER, van Iersel EE, et al. 2007. Prevalence of patients using drugs metabolized by cytochrome P450 2D6 in different populations: a crosssectional study. Ann Pharmacother. 41:406-413.
  4. Altar CA, Hornberger J, Shewade A, Cruz V, Garrison J, Mrazek D. 2013. Int Rev Psychiatry. Clinical validity of cytochrome P450 metabolism and serotonin gene variants in psychiatric pharmacotherapy. 25:509-33
  5. Mrazek DA. 2010. Psychiatric pharmacogenomic testing in clinical practice. Dialogues Clin Neurosci. 12:69-76. Review.
  6. Angst MS, Phillips NG, Drover DR, et al. Pain sensitivity and opioid analgesia: a pharmacogenomic twin study. Pain. 2012;153(7):1397-409.
  7. Reynolds KK, Ramey-Hartung B, Jortani SA. The value of CYP2D6 and OPRM1 pharmacogenetic testing for opioid therapy. Clin Lab Med. 2008;28(4):581-598.
  8. Webster LR. Pharmacogenetics in pain management: the clinical need. Clin Lab Med. 2008;28(4):569-579.
  9. Droney J, Riley J, Ross J. Opioid genetics in the context of opioid switching. Curr Opin Support Palliat Care. 2012;6(1):10-16.
  10. Jannetto PJ, Bratanow NC. Pain management in the 21st century: utilization of pharmacogenomics and therapeutic drug monitoring. Expert Opin Drug Metab Toxicol. 2011;7(6):745-752.
  11. Eichner et al. Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. Am J Epidemiol. 2002, 155(6):487-95.
  12. Koch et al. Apolipoprotein E gene epsilon2/epsilon3/epsilon4 polymorphism and myocardial infarction: case-control study in a large population sample. Int J Cardiol. 2008, 125(1):116-7.
  13. Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet. 2009;48(11):689-723.
  14. Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin Pharmacokinet. 2009;48(12):761-804.